Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Impact · against what's priced in

The Brazilian approval of NIKTIMVO is a positive regulatory milestone for Knight Therapeutics and a modest win for Incyte's post-Jakafi portfolio. While it supports the long-term growth narrative for Incyte, the small scale of the Brazilian market relative to Incyte's total revenue means the price impact is minimal.

INCY+0.10

Challenges what's priced in

The price assumes

The bull case that the post-Jakafi portfolio reaches a $3-4bn run rate growing at 20% annually

The regulatory approval of NIKTIMVO in Brazil contributes to the diversification of the post-Jakafi portfolio, which the market currently treats as a flat continuation of the status quo.

What INCY's price assumes · Sep 22

• pharmaceuticals
• GUD
• INCY
• biotechnology
• brazil
• latin america
• rare disease
• regulatory approval

Search tags